I'd be very disappointed (provided Lupozor passes it's trials and the other compounds in development show real potential) if IMM was sold for less than £2.5bn. I'd be hoping to see in excess of $3.6bn if Lupozor proves to be significantly more effective than other drugs on the market.
This then brings us into some of the impressive valuations that Sicilian Kan came up with a few weeks ago based on conservative figures.
WTFDIK when it comes to predicting a potential takeover price!
Does anybody know any sources comparing the success of treatment by Lupuzor vs treatment by Benelysta? A quick bit of research shows that the company which developed Benelysta sold to GSK for $3.6bn (although they did also have a few other drugs in development)
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.